|
業務類別
|
Biotechnology |
|
業務概覽
|
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health. |
| 公司地址
| 8 Davis Drive, Suite 220, Durham, NC, USA, 27713 |
| 電話號碼
| +1 984 884-6030 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.opusgtx.com |
| 員工數量
| 28 |
| Mr. Joseph K. Schachle |
Chief Operating Officer |
-- |
23/03/2026 |
| Dr. Benjamin R. Yerxa,PhD |
Director and President |
-- |
23/03/2026 |
| Dr. George Magrath, PhD |
Director and Chief Executive Officer |
-- |
23/03/2026 |
| Mr. Robert Gagnon, M.B.A. |
Chief Financial Officer and Principal Accounting Officer |
-- |
23/03/2026 |
| Ms. Amy Rabourn |
Head, Financial Quality Assurance |
-- |
23/03/2026 |
| Dr. Ashwath Jayagopal, PhD |
Chief Scientific and Development Officer |
-- |
23/03/2026 |
|
|
| Dr. Benjamin R. Yerxa,PhD |
Director and President |
23/03/2026 |
| Dr. George Magrath, PhD |
Director and Chief Executive Officer |
23/03/2026 |
| Dr. Adrienne L. Graves,PhD |
Independent Director |
23/03/2026 |
| Dr. Jean Bennett, M.D.,Pd.D |
Director |
23/03/2026 |
| Dr. James S.J. Manuso, M.B.A.,PhD |
Independent Director |
23/03/2026 |
| Mr. Cam S. Gallagher |
Chairman of the Board |
23/03/2026 |
| Mr. Sean Ainsworth |
Lead Independent Director |
23/03/2026 |
| Ms. Susan K. Benton |
Independent Director |
23/03/2026 |
| Mr. Richard J. Rodgers |
Independent Director |
23/03/2026 |
|
|
|
|
